病理性疼痛:帕金森病及其治疗中的非运动表现
Jing Lei1, Lin-Lin Tang2, Hao-Jun You1
1Center for Translational Medicine Research on Sensory-Motor Diseases, Yan'an University, Yan'an 716000, China; Key Laboratory of Yan'an Sports Rehabilitation Medicine, Yan'an 716000, China.
Neuroscience and biobehavioral reviews
|April 3, 2024
概括
帕金森病 (PD) 疼痛,通常是早期症状,源于改变影响疼痛信号的大脑路径. 了解下降调制中的这些变化是有效管理PD疼痛的关键.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 疼痛研究 疼痛研究
背景情况:
- 帕金森病 (PD) 呈现出运动和非运动症状,包括疼痛,抑郁和睡眠障碍.
- 疼痛是PD中普遍存在的非运动性症状,通常在运动缺陷之前,甚至在早期出现.
- 患PD疼痛的确切机制是复杂的,涉及神经递质系统功能障碍.
研究的目的:
- 为了审查帕金森病中疼痛的发病和进展.
- 专注于PD中 nociception的中央调制.
- 探索内源性下降途径在PD疼痛中的作用.
主要方法:
- 文献综述专注于帕金森病中的疼痛.
- 对中央疼痛调节和神经递质系统的研究分析.
- 检查多巴胺基和非多巴胺基途径的作用.
主要成果:
- 在PD中失去多巴氨基神经元会导致脊柱上结构的功能缺陷.
- 这导致内源性下降疼痛调节的失衡,包括促进和抑制.
- 非多巴胺基系统也受到影响,导致异常的疼痛处理.
结论:
- 改变 nociception 的中央调制,特别是下降途径,在PD 疼痛中至关重要.
- 了解这些机制,可以了解PD疼痛的性质.
- 这些知识可以指导开发PD疼痛的有效临床管理策略.
相关概念视频
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Analgesia and Pain Management
614
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
614
Nociception
27.9K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
27.9K
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184


